PE20110028A1 - Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato - Google Patents

Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato

Info

Publication number
PE20110028A1
PE20110028A1 PE2010001111A PE2010001111A PE20110028A1 PE 20110028 A1 PE20110028 A1 PE 20110028A1 PE 2010001111 A PE2010001111 A PE 2010001111A PE 2010001111 A PE2010001111 A PE 2010001111A PE 20110028 A1 PE20110028 A1 PE 20110028A1
Authority
PE
Peru
Prior art keywords
isoxazole
dihydro
chloro
alkyl
metabotropic glutamate
Prior art date
Application number
PE2010001111A
Other languages
English (en)
Spanish (es)
Inventor
Joseph Cacciola
James Empfield
James Folmer
Angela M Hunter
Scott Throner
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20110028A1 publication Critical patent/PE20110028A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods
    • A61B17/08Wound clamps or clips, i.e. not or only partly penetrating the tissue ; Devices for bringing together the edges of a wound
    • A61B17/083Clips, e.g. resilient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods
    • A61B17/08Wound clamps or clips, i.e. not or only partly penetrating the tissue ; Devices for bringing together the edges of a wound
    • A61B17/085Wound clamps or clips, i.e. not or only partly penetrating the tissue ; Devices for bringing together the edges of a wound with adhesive layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods
    • A61B17/10Surgical instruments, devices or methods for applying or removing wound clamps, e.g. containing only one clamp or staple; Wound clamp magazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods
    • A61B17/10Surgical instruments, devices or methods for applying or removing wound clamps, e.g. containing only one clamp or staple; Wound clamp magazines
    • A61B17/105Wound clamp magazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Surgery (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PE2010001111A 2008-06-06 2009-06-08 Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato PE20110028A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5948508P 2008-06-06 2008-06-06

Publications (1)

Publication Number Publication Date
PE20110028A1 true PE20110028A1 (es) 2011-02-11

Family

ID=41398335

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2010001111A PE20110028A1 (es) 2008-06-06 2009-06-08 Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato

Country Status (40)

Country Link
US (4) US7790760B2 (enExample)
EP (2) EP2772492B1 (enExample)
JP (2) JP5476371B2 (enExample)
KR (1) KR20110020797A (enExample)
CN (1) CN102105466B (enExample)
AR (1) AR072016A1 (enExample)
AU (1) AU2009255784B2 (enExample)
BR (1) BRPI0913585A2 (enExample)
CA (1) CA2726925A1 (enExample)
CL (1) CL2010001348A1 (enExample)
CO (1) CO6321239A2 (enExample)
CR (1) CR11826A (enExample)
CU (1) CU23883B1 (enExample)
CY (1) CY1115301T1 (enExample)
DK (1) DK2303872T3 (enExample)
DO (1) DOP2010000375A (enExample)
EA (2) EA018412B1 (enExample)
EC (1) ECSP10010662A (enExample)
ES (1) ES2469837T3 (enExample)
GT (1) GT201000342A (enExample)
HK (1) HK1201255A1 (enExample)
HN (1) HN2010002582A (enExample)
HR (1) HRP20140451T1 (enExample)
IL (1) IL209622A0 (enExample)
MX (1) MX2010012949A (enExample)
MY (1) MY156552A (enExample)
NI (3) NI201000209A (enExample)
NZ (1) NZ590344A (enExample)
PE (1) PE20110028A1 (enExample)
PL (1) PL2303872T3 (enExample)
PT (1) PT2303872E (enExample)
RS (1) RS53392B (enExample)
SA (1) SA109300358B1 (enExample)
SI (1) SI2303872T1 (enExample)
SV (1) SV2010003751A (enExample)
TW (3) TWI382027B (enExample)
UA (1) UA107649C2 (enExample)
UY (1) UY31870A (enExample)
WO (1) WO2009148403A1 (enExample)
ZA (1) ZA201008611B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
ES2409215T3 (es) 2007-09-14 2013-06-25 Janssen Pharmaceuticals, Inc. 4-fenil-1H-piridin-2-onas 1-3-disustituidas
US7790760B2 (en) * 2008-06-06 2010-09-07 Astrazeneca Ab Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
CA2738849C (en) 2008-10-16 2016-06-28 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
SG176018A1 (en) 2009-05-12 2011-12-29 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2440001T3 (es) 2009-05-12 2014-01-27 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-A]piridina y su uso para el tratamiento o prevención de trastornos neurológicos y psiquiÔtricos
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2552455T3 (es) 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostƩricos positivos de receptores mGluR2
CN103298809B (zh) 2010-11-08 2016-08-31 ęØę£®åˆ¶čÆå…¬åø 1,2,4-三唑并[4,3-a]å”å•¶č”ē”Ÿē‰©åŠå…¶ä½œäøŗMGLUR2å—ä½“ēš„ę­£å˜ęž„č°ƒčŠ‚å‰‚ēš„ē”Øé€”
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv Ł…Ų±ŁƒŲØŲ§ŲŖ 6، 7- Ų«Ų§Ł†ŁŠ Ł‡ŁŠŲÆŲ±Łˆ ŲØŁŠŲ±Ų§Ų²ŁˆŁ„Łˆ [5،1-a] ŲØŁŠŲ±Ų§Ų²ŁŠŁ†- 4 (5 يد)- Ų§ŁˆŁ† ŁˆŲ§Ų³ŲŖŲ®ŲÆŲ§Ł…Ł‡Ų§ بصفة منظمات تفارغية Ų³Ł„ŲØŁŠŲ© لمستقبلات Ł…ŁŠŲ¬Ł„ŁˆŲ± 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv Ł…Ų±ŁƒŲØŲ§ŲŖ 2،1، 4- Ų«Ł„Ų§Ų«ŁŠ Ų²ŁˆŁ„Łˆ [3،4-a] ŲØŁŠŲ±ŁŠŲÆŁŠŁ† ŁˆŲ§Ų³ŲŖŲ®ŲÆŲ§Ł…Ł‡Ų§ بصفة منظمات تفارغية Ł…ŁˆŲ¬ŲØŲ© لمستقبلات Ł…ŁŠŲ¬Ł„ŁˆŲ± 2
US10537573B2 (en) 2014-01-21 2020-01-21 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
IL279202B2 (en) 2014-01-21 2023-09-01 Janssen Pharmaceutica Nv Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use
WO2015157187A1 (en) 2014-04-06 2015-10-15 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor positive allosteric modulators (pams) and uses thereof
KR101663662B1 (ko) * 2015-06-17 2016-10-14 ķ•œźµ­ź³¼ķ•™źø°ģˆ ģ—°źµ¬ģ› ėŒ€ģ‚¬ģ„± źø€ė£Øķƒ€ė©”ģ“ķŠø 수용첓 1에 ķ™œģ„±ģ„ ģ§€ė‹Œ ģ‹ ź·œ 아릓 ģ•„ģ“ģ†Œģ˜„ģ‚¬ģ”ø ģœ ė„ģ²“
US20170145002A1 (en) * 2015-11-25 2017-05-25 Astrazeneca Ab Deuterated isoxazole derivatives and their use as metabotropic glutamate receptor potentiators
WO2020102150A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors
WO2020102198A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE620654C (de) 1933-04-29 1935-10-24 Smith & Sons Ltd S Geschwindigkeitsanzeiger
US3993617A (en) * 1975-10-30 1976-11-23 Morton-Norwich Products, Inc. Antifungal 2-substituted phthalimidines
US5175157A (en) * 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
WO1992017448A1 (fr) 1991-04-01 1992-10-15 Kyowa Hakko Kogyo Co., Ltd. Derive de 3-methylenisoindolin-1-one
TW219935B (enExample) 1991-12-25 1994-02-01 Mitsubishi Chemicals Co Ltd
EP0602814A1 (en) 1992-12-18 1994-06-22 Takeda Chemical Industries, Ltd. Crystal forms of optically active isoindolines and their use
US5681954A (en) * 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
AU1618697A (en) * 1996-02-06 1997-08-28 Japan Tobacco Inc. Novel compounds and pharmaceutical use thereof
AU7548298A (en) 1997-05-30 1998-12-30 Meiji Seika Kaisha Ltd. Nitrogenous heterocyclic compounds and hyperlipemia remedy containing the same
IL136250A0 (en) 1997-11-21 2001-05-20 Nps Pharma Inc Metabotropic glutamate receptor antagonist compounds
NZ521576A (en) * 2000-02-29 2005-06-24 Mitsubishi Pharma Corp Novel cyclic amide derivatives
HUP0302966A2 (hu) 2000-07-31 2003-12-29 Smithkline Beecham P.L.C. Karboxamid-vegyületek Ć©s alkalmazĆ”suk humĆ”n 11CBY receptor antagonistĆ”kkĆ©nt, eljĆ”rĆ”s az előÔllĆ­tĆ”sukra Ć©s ezeket tartalmazó gyógyszerkĆ©szĆ­tmĆ©nyek
BR0211810A (pt) 2001-08-09 2004-08-24 Ono Pharmaceutical Co Derivados Ôcido carboxìlico e agente farmacêutico compreendendo os mesmos como ingrediente ativo
WO2003087044A2 (en) 2002-04-09 2003-10-23 7Tm Pharma A/S Novel carboxamide compounds for use in mch receptor related disorders
FR2840302B1 (fr) 2002-06-03 2004-07-16 Aventis Pharma Sa Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
DE10238865A1 (de) 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue CarbonsƤureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB0223232D0 (en) 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
US7507836B2 (en) 2003-03-26 2009-03-24 Merck & Co. Inc. Benzamide modulators of metabotropic glutamate receptors
GB0308025D0 (en) 2003-04-07 2003-05-14 Glaxo Group Ltd Compounds
US7129260B2 (en) * 2003-06-02 2006-10-31 Abbott Laboratories Isoindolinone kinase inhibitors
WO2005040157A2 (en) 2003-10-22 2005-05-06 Eli Lilly And Company Novel mch receptor antagonists
WO2005074643A2 (en) 2004-01-30 2005-08-18 Smithkline Beecham Corporation Benzamide compounds useful as rock inhibitors
EP1716152B1 (en) 2004-02-18 2008-07-30 AstraZeneca AB Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders
EP1726585A4 (en) 2004-03-05 2009-07-15 Banyu Pharma Co Ltd DIARYLSUBSTITUTED FIVE-GLOSS HETEROCYCLUS DERIVAT
CN1930136B (zh) 2004-03-05 2012-02-08 ę—„äŗ§åŒ–å­¦å·„äøšę Ŗå¼ä¼šē¤¾ 异*å”‘å•‰å–ä»£č‹Æē”²é…°čƒŗåŒ–åˆē‰©åŠęœ‰å®³ē”Ÿē‰©é˜²é™¤å‰‚
SE0400970D0 (sv) 2004-04-14 2004-04-14 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
AU2005299797A1 (en) 2004-10-25 2006-05-04 Merck & Co., Inc. Heterocyclic indanone potentiators of metabotropic glutamate receptors
WO2006091496A2 (en) 2005-02-24 2006-08-31 Merck & Co., Inc. Benzazole potentiators of metabotropic glutamate receptors
KR20080027463A (ko) 2005-05-18 2008-03-27 ģ•„ė±ģŠ¤ 파마 ģ—ģŠ¤ģ—ģ“ ėŒ€ģ‚¬ģ„± źø€ė£Øķƒ€ė©”ģ“ķŠø ģˆ˜ģš©ģ²“ģ˜ 양성 ģ•Œė”œģŠ¤ķ…Œė¦­ģ”°ģ ˆģžė”œģ„œģ˜ ģ¹˜ķ™˜ėœ ģ˜„ģ‚¬ė””ģ•„ģ”ø ģœ ė„ģ²“
GB0510142D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
TW200728277A (en) 2005-06-29 2007-08-01 Palau Pharma Sa Bicyclic derivatives as P38 inhibitors
US7868008B2 (en) 2005-08-12 2011-01-11 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
US7807706B2 (en) * 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
JP5031745B2 (ja) * 2005-08-12 2012-09-26 ć‚¢ć‚¹ćƒˆćƒ©ć‚¼ćƒć‚« ć‚¢ć‚Æćƒćƒœćƒ©ć‚° ä»£č¬åž‹ć‚°ćƒ«ć‚æćƒŸćƒ³é…øå—å®¹ä½“å¢—å¼·ę€§ć‚¤ć‚½ć‚¤ćƒ³ćƒ‰ćƒ­ćƒ³
ES2340321T3 (es) 2005-09-27 2010-06-01 F.Hoffmann-La Roche Ag Oxadiazolilpirazolo-pirimidinas, como antagonistas de mglur2.
TW200804281A (en) 2006-02-16 2008-01-16 Astrazeneca Ab New metabotropic glutamate receptor-potentiating isoindolones
TWI417100B (zh) * 2007-06-07 2013-12-01 Astrazeneca Ab ļ˜–äŗŒå”‘č”ē”Ÿē‰©åŠå…¶ä½œē‚ŗä»£č¬åž‹éŗ©čƒŗé…øå—é«”å¢žę•ˆåŠ‘-ļ¼˜ļ¼”ļ¼’ä¹‹ē”Øé€”
TW200911255A (en) * 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
US7790760B2 (en) * 2008-06-06 2010-09-07 Astrazeneca Ab Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286

Also Published As

Publication number Publication date
PL2303872T3 (pl) 2014-08-29
JP2014114312A (ja) 2014-06-26
TW201247658A (en) 2012-12-01
EA018412B1 (ru) 2013-07-30
BRPI0913585A2 (pt) 2015-10-27
US8148372B2 (en) 2012-04-03
WO2009148403A1 (en) 2009-12-10
HN2010002582A (es) 2012-08-27
AU2009255784A1 (en) 2009-12-10
CU23883B1 (es) 2013-04-19
CL2010001348A1 (es) 2011-03-25
NZ590344A (en) 2012-07-27
CR11826A (es) 2011-02-04
US20100324044A1 (en) 2010-12-23
US20100022545A1 (en) 2010-01-28
CA2726925A1 (en) 2009-12-10
TW201514173A (zh) 2015-04-16
US20100317662A1 (en) 2010-12-16
PT2303872E (pt) 2014-06-23
NI201000209A (es) 2012-11-07
KR20110020797A (ko) 2011-03-03
ZA201008611B (en) 2012-05-30
EP2303872A1 (en) 2011-04-06
CY1115301T1 (el) 2017-01-04
MY156552A (en) 2016-02-26
HK1201255A1 (en) 2015-08-28
JP5476371B2 (ja) 2014-04-23
JP5815765B2 (ja) 2015-11-17
EP2772492B1 (en) 2016-08-17
SV2010003751A (es) 2011-04-14
SA109300358B1 (ar) 2012-11-03
EA201001724A1 (ru) 2011-08-30
TWI382027B (zh) 2013-01-11
IL209622A0 (en) 2011-02-28
US7790760B2 (en) 2010-09-07
ES2469837T3 (es) 2014-06-20
MX2010012949A (es) 2010-12-15
UA107649C2 (uk) 2015-02-10
DK2303872T3 (da) 2014-06-16
NI201002091A (es) 2012-11-07
EP2772492A1 (en) 2014-09-03
UY31870A (es) 2010-01-29
US20090306158A1 (en) 2009-12-10
DOP2010000375A (es) 2010-12-31
US7781434B2 (en) 2010-08-24
US7888353B2 (en) 2011-02-15
EP2303872B1 (en) 2014-04-16
TWI477499B (zh) 2015-03-21
ECSP10010662A (es) 2011-01-31
CN102105466A (zh) 2011-06-22
EA201300342A1 (ru) 2014-02-28
AR072016A1 (es) 2010-07-28
GT201000342A (es) 2015-02-16
HK1155744A1 (en) 2012-05-25
AU2009255784B2 (en) 2012-08-16
CO6321239A2 (es) 2011-09-20
SI2303872T1 (sl) 2014-06-30
HRP20140451T1 (hr) 2014-08-01
RS53392B (sr) 2014-10-31
NI201002092A (es) 2012-11-07
CU20100238A7 (es) 2011-11-15
EP2303872A4 (en) 2012-03-21
TW201002699A (en) 2010-01-16
CN102105466B (zh) 2014-10-15
JP2011522816A (ja) 2011-08-04

Similar Documents

Publication Publication Date Title
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
PE20141827A1 (es) Inhibidores de proteinas quinasas
CO6300954A2 (es) Derivados de tienopiridinonas como activadores de proteina quinasa activados por ampk
PE20090884A1 (es) Compuestos de indol como activadores de glucoquinasa
PE20120031A1 (es) Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
PE20091724A1 (es) Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
PE20081229A1 (es) Antagonistas de receptor de orexina de diazepam sustituido
PE20130155A1 (es) Derivados de ariletinilo
PE20141228A1 (es) Derivados de pirrolopirimidina y purina
PE20140207A1 (es) Composiciones y metodos para modular el fxr
PE20121158A1 (es) Derivados de feniletinilo como moduladores alostericos positivos (map)
PE20070585A1 (es) Derivados de sulfonamida como activadores de glucoquinasa
PE20081800A1 (es) NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA
PE20090641A1 (es) Amidas heterociclicas
PE20080150A1 (es) Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch)
PE20110852A1 (es) Antagonistas del receptor de orexina de isonicotinamida
ECSP10010654A (es) Derivados de tienopiridonas como activadores de proteĆ­na quinasa activados por amp (ampk)
DOP2007000018A (es) Moduladores de indol sulfonamida de receptores de progesterona
PE20120561A1 (es) Compuestos que modulan selectivamente el receptor cb2
PE20071156A1 (es) COMPUESTOS DERIVADOS DE 4,5,6,7-TETRAHIDRO-1H-INDAZOL COMO POTENCIADORES DEL RECEPTOR DEL ACIDO a-AMINO-3-HIDROXI-5-METILISOXAZOL-4-PROPIONICO (AMPA)
PE20140934A1 (es) Derivados de pirazol
PE20110196A1 (es) 5-alquinil-pirimidinas
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
PE20081753A1 (es) Compuestos y composiciones como inhibidores de la proteasa activadora de canal

Legal Events

Date Code Title Description
FA Abandonment or withdrawal